Form 8-K - Current report:
SEC Accession No. 0000950170-23-021996
Filing Date
2023-05-15
Accepted
2023-05-15 09:03:13
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K spry-20230515.htm   iXBRL 8-K 76107
2 EX-99.1 spry-ex99_1.htm EX-99.1 230541
3 GRAPHIC img41264513_0.jpg GRAPHIC 32408
  Complete submission text file 0000950170-23-021996.txt   494103

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spry-20230515.xsd EX-101.SCH 2468
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spry-20230515_pre.xml EX-101.PRE 11556
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spry-20230515_lab.xml EX-101.LAB 18676
8 EXTRACTED XBRL INSTANCE DOCUMENT spry-20230515_htm.xml XML 4893
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 23918823
SIC: 2834 Pharmaceutical Preparations